NACCHO to donate up to one million doses of FluMist
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise. At Cold Spring Harbor Laboratory (CSHL), five different research groups have now combined their expertise to speed up the rate of discovering cancer-related genes and validating their function in living animals. The result of the collaborative
Full Post: Discovery of 13 new tumor-suppressor genes in liver cancer
The National Association of County and City Health Officials (NACCHO) has announced a donation of up to one million doses of FluMist (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations.
NACCHO will make these donated doses of vaccine available to selected state and local health departments around the country starting this month. This joint NACCHO-MedImmune effort supports the goal of the Centers for Disease Control and Prevention (CDC) to broaden the influenza vaccination season into December and beyond. The CDC has launched National Influenza Vaccination Week (December 8-12) as a springboard to help educate the public on the importance of influenza vaccination throughout the winter. Vaccination rates typically decline after Thanksgiving, although the peak of influenza season usually occurs in February and March.
“NACCHO is pleased to partner with MedImmune to help increase the number of individuals vaccinated against influenza,” said NACCHO President Gary Cox, J.D. “These doses of vaccine will go a long way to support a national objective of immunizing all persons who should receive flu vaccine, especially those who are least able to afford it.”
Public health guidelines on annual influenza vaccination are broader than ever before. In February 2008, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand pediatric influenza vaccination recommendations to include school-age children ages 5 through 18 years. The expanded recommendations add 30 million children to the recommended pediatric population for annual influenza vaccination. In addition to influenza vaccination recommendations for specific populations (http://www.cdc.gov/flu), the CDC recommends that anyone who wants to reduce their chances of getting influenza or spreading it to others get vaccinated every year.
“We are proud to support NACCHO’s objective of increasing flu vaccination rates across the country,” stated Brian Rosen, MedImmune’s senior director, government relations. “We at MedImmune take great pride in knowing this donation may help protect up to one million more eligible men, women, and children against influenza, and educate them about the importance of protecting themselves and their families against influenza.”
FluMist is a live attenuated influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.
Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.
If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.
Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.
FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine. This suggests that half-dose vaccination in healthy young individuals may be
Full Post: Half-dose vaccination in healthy young individuals may be effective in times of vaccine shortage
Although naturally occurring smallpox was eradicated in 1977, there is concern that bioterrorists might obtain smallpox from a laboratory and release it into the population. Under such circumstances, the supply of smallpox vaccine may be insufficient for universal administration. In a study published in the December 2008 issue of The American Journal of Medicine, researchers
Full Post: New study indicates smallpox vaccination effective for decades
Novavax, Inc. has announced favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate. The vaccine, which does not include an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to correlate with protection against seasonal influenza disease. The Phase IIa randomized, placebo-controlled clinical trial evaluated
Full Post: Novavax announces positive results in trial of seasonal influenza VLP (trivalent) vaccine candidate
Despite recent doubts about its effectiveness, the influenza vaccine does give valuable protection against illness, hospital admission and death caused by influenza, and people over 65 should have the flu jab this winter, say experts on bmj.com. Several prominent media articles have suggested that the flu vaccination programme for the over 65s is not worthwhile.
Full Post: Seniors should have the flu jab this winter, say experts
Workers age 50-64 who received influenza vaccine lost substantially fewer days of work and worked fewer days while ill, according to a new study in the Feb. 1 issue of Clinical Infectious Diseases, now available online. Given the concerns about antiviral drug resistance among this year’s flu strains, the study highlights the importance of vaccination
Full Post: Influenza vaccine helps 50-64 year olds stay at work